Irina is a trained neurologist and psychiatrist, board certified in Germany; she obtained her venia legendi from the Berlin University and has a PhD in neurophysiology from the UK. During her residency training in Germany and the US Irina has treated many patients with various neuropsychiatric disorders. In 2001, she moved to industry with the goal to develop better therapeutics for unmet needs, such as many neuropsychiatric disorders. Her drug development efforts have focused on translational medicine and early development of therapeutics for rare genetic diseases. In 2009/2010 Irina was Medical Director at CHDI, a non-profit foundation focused on Huntington disease. Irina has remained committed to develop new therapeutics for Huntington disease and other are genetic neuropsychiatric disorders while working in global pharma, such as Sanofi Genzyme, as well as small biotech, such as Triplet Therapeutics. Triplet is developing nucleic acid therapeutics to address the enormous unmet need in HD and other Repeat Expansion Disorders.